Neurologist. Deputy director of Cemcat

  • Member of the Steering Committee of MAGNIMS
  • Member of the Executive Board of RIMS
  • Member of the Editorial Board of the Multiple Sclerosis Journal
  • Director of Revista de Neurología

Education

Dr. Jaume Sastre-Garriga received his MD at the University of Barcelona and his PhD at the Universitat Autònoma de Barcelona. He trained as a neurologist at the Neurology Department, Vall d’Hebron University Hospital.


Career

From June 2002 to December 2004 he was a awarded a grant from the Spanish Ministry of Health and held a post as a clinical research fellow at the MRI and Neurorehabilitation units, Institute of Neurology, London, under the mentorship of Professor Alan Thompson. In 2004 and 2005 he was awarded by the Spanish Society of Neurology (SEN) the prize for the best Spanish paper in an international neurological journal. From January 2005 to February 2007 Dr. Sastre-Garriga was Medical Director of the neurorehabilitation centres of the MS Foundation in Catalonia. Since March 2007 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology, MS Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital (Barcelona).


Projects / Lines of Research / Interests

His main interests are magnetic resonance imaging techniques (functional MRI and volumetry) and neurorehabilitation with a special focus on the primary progressive forms of MS, a disease type to which he devoted his PhD research.


Publications

The last 100 publications:

  1. Otero-Romero S, Midaglia L, Carbonell-Mirabent P, Zuluaga M, Galán I, Río J, Arrambide G, Rodríguez-Barranco M, Vidal-Jordana A, Castillo J, Rodríguez-Acevedo B, Zabalza A, Nos C, Comabella Lopez M, Mulero P, Auger C, Sastre-Garriga J, Pérez-Hoyos S, Rovira A, Montalban X, Tintoré M. Menopause does not modify disability trajectories in a longitudinal cohort of women with CIS and MS followed from disease onset. Eur J Neurol. 2021 Feb 20. PMID: 33609298

  2. Midaglia L, Sastre-Garriga J, Pappolla A, Quibus L, Carvajal R, Vidal-Jordana A, Arrambide G, Río J, Comabella M, Nos C, Castilló J, Galan I, Rodríguez-Acevedo B, Auger C, Tintoré M, Montalban X, Rovira À. The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Mult Scler. 2021 Feb 10. PMID: 33565909

  3. Roca-Fernández A, Oertel FC, Yeo T, Motamedi S, Probert F, Craner MJ, Sastre-Garriga J, Zimmermann HG, Asseyer S, Kuchling J, Bellmann-Strobl J, Ruprecht K, Leite MI, Paul F, Brandt AU, Palace J. Foveal changes in AQP4-Ab seropositive NMOSD are independent of optic neuritis and not overtly progressive. Eur J Neurol. 2021 Feb 6. PMID: 33547839

  4. Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira A, Sastre-Garriga J, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Bisecco A, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Filippi M, MAGNIMS Study Group.. Association of Gray Matter Atrophy Patterns with Clinical Phenotype and Progression in Multiple Sclerosis. Neurology. 2021 Jan 13. PMID: 33441452

  5. Chard DT, Alahmadi AAS, Audoin B, Charalambous T, Enzinger C, Hulst HE, Rocca MA, Rovira À, Sastre-Garriga J, Schoonheim MM, Tijms B, Tur C, Gandini Wheeler-Kingshott CAM, Wink AM, Ciccarelli O, Barkhof F, MAGNIMS Study Group.. Mind the gap: from neurons to networks to outcomes in multiple sclerosis. Nat Rev Neurol. 2021 Jan 12. PMID: 33437067

  6. Burggraaff J, Liu Y, Prieto JC, Simoes J, de Sitter A, Ruggieri S, Brouwer I, Lissenberg-Witte BI, Rocca MA, Valsasina P, Ropele S, Gasperini C, Gallo A, Pareto D, Sastre-Garriga J, Enzinger C, Filippi M, De Stefano N, Ciccarelli O, Hulst HE, Wattjes MP, Barkhof F, Uitdehaag BMJ, Vrenken H, Guttmann CRG, MAGNIMS Study Group.. Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. Neuroimage Clin. 2021. PMID: 33401136

  7. Zabalza A, Cárdenas-Robledo S, Tagliani P, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Rodriguez-Barranco M, Rodríguez-Acevedo B, Restrepo Vera JL, Resina-Salles M, Midaglia L, Vidal-Jordana A, Río J, Galan I, Castillo J, Cobo-Calvo Á, Comabella M, Nos C, Sastre-Garriga J, Tintore M, Montalban X. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol. 2020 Dec 19. PMID: 33340215

  8. Vidal-Jordana A, Rovira A, Arrambide G, Otero-Romero S, Río J, Comabella M, Nos C, Castilló J, Galan I, Cabello S, Moncho D, Rahnama K, Thonon V, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Auger C, Sastre-Garriga J, Montalban X, Tintoré M. Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. Neurology. 2021 Jan 26. PMID: 33328323

  9. Pérez-Miralles FC, Río J, Pareto D, Vidal-Jordana À, Auger C, Arrambide G, Castilló J, Tintoré M, Rovira À, Montalban X, Sastre-Garriga J. Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score. Neuroradiology. 2020 Nov 25. PMID: 33237430

  10. Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T, Husak S, McGinley MP, Ontaneda D, Wang Z, Weber M, Tagliani P, Cárdenas-Robledo S, Zabalza A, Arrambide G, Carbonell-Mirabent P, Rodríguez-Barranco M, Sastre-Garriga J, Tintore M, Montalban X, Douglas M, Ogbuokiri E, Aravidis B, Cohen JA, Mowry EM, Fitzgerald KC. Multiple sclerosis management during the COVID-19 pandemic. Mult Scler. 2020 Sep. PMID: 32772807

  11. Geraldes R, Juryńczyk M, Dos Passos GR, Pichler A, Chung K, Hagens M, Ruggieri S, Auger C, Sastre-Garriga J, Enzinger C, Chard D, Barkhof F, Gasperini C, Rovira A, DeLuca G, Palace J, MAGNIMS study group.. The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. Mult Scler. 2020 Aug 6. PMID: 32757905

  12. Vidal-Jordana A, Pareto D, Cabello S, Alberich M, Rio J, Tintore M, Auger C, Montalban X, Rovira A, Sastre-Garriga J. Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. Eur J Neurol. 2020 Nov. PMID: 32602573

  13. Sastre-Garriga J, Tintoré M, Montalban X. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Mult Scler. 2020 Sep. PMID: 32552382

  14. Solari A, Giordano A, Sastre-Garriga J, Köpke S, Rahn AC, Kleiter I, Aleksovska K, Battaglia MA, Bay J, Copetti M, Drulovic J, Kooij L, Mens J, Meza Murillo ER, Milanov I, Milo R, Pekmezovic T, Vosburgh J, Silber E, Veronese S, Patti F, Voltz R, Oliver D, guideline task force.. EAN guideline on palliative care of people with severe, progressive multiple sclerosis. Eur J Neurol. 2020 Aug. PMID: 32469447

  15. Solari A, Giordano A, Sastre-Garriga J, Köpke S, Rahn AC, Kleiter I, Aleksovska K, Battaglia MA, Bay J, Copetti M, Drulovic J, Kooij L, Mens J, Murillo ERM, Milanov I, Milo R, Pekmezovic T, Vosburgh J, Silber E, Veronese S, Patti F, Voltz R, Oliver DJ. EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. J Palliat Med. 2020 Nov. PMID: 32469284

  16. Clarke MA, Pareto D, Pessini-Ferreira L, Arrambide G, Alberich M, Crescenzo F, Cappelle S, Tintoré M, Sastre-Garriga J, Auger C, Montalban X, Evangelou N, Rovira À. Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. AJNR Am J Neuroradiol. 2020 Jun. PMID: 32439639

  17. Robles-Sanchez MA, Cruz-Díaz V, Amil-Bujan P, Sastre-Garriga J, Ramió-Torrentà L, Bertran-Noguer C. An Expert Patient Program as a Tool to Empower People With Multiple Sclerosis. J Neurosci Nurs. 2020 Aug. PMID: 32398626

  18. Cole JH, Raffel J, Friede T, Eshaghi A, Brownlee WJ, Chard D, De Stefano N, Enzinger C, Pirpamer L, Filippi M, Gasperini C, Rocca MA, Rovira A, Ruggieri S, Sastre-Garriga J, Stromillo ML, Uitdehaag BMJ, Vrenken H, Barkhof F, Nicholas R, Ciccarelli O, MAGNIMS study group.. Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm. Ann Neurol. 2020 Jul. PMID: 32285956

  19. Derfuss T, Sastre-Garriga J, Montalban X, Rodegher M, Wuerfel J, Gaetano L, Tomic D, Azmon A, Wolf C, Kappos L. The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2020 Jan-Mar. PMID: 32284874

  20. Cappelle S, Pareto D, Tintoré M, Vidal-Jordana A, Alyafeai R, Alberich M, Sastre-Garriga J, Auger C, Montalban X, Rovira À. A validation study of manual atrophy measures in patients with Multiple Sclerosis. Neuroradiology. 2020 Aug. PMID: 32246177

  21. Pareto D, Garcia-Vidal A, Alberich M, Auger C, Montalban X, Tintoré M, Sastre-Garriga J, Rovira À. Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol. 2020 Mar. PMID: 32139431

  22. Sastre-Garriga J, Pareto D, Battaglini M, Rocca MA, Ciccarelli O, Enzinger C, Wuerfel J, Sormani MP, Barkhof F, Yousry TA, De Stefano N, Tintoré M, Filippi M, Gasperini C, Kappos L, Río J, Frederiksen J, Palace J, Vrenken H, Montalban X, Rovira À, MAGNIMS study group.. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol. 2020 Mar. PMID: 32094485

  23. Geraldes R, Juryńczyk M, Dos Passos G, Prichler A, Chung K, Hagens M, Ruggieri S, Huerga E, Sastre-Garriga J, Enzinger C, Chard DT, Barkhof F, Gasperini C, Rovira A, DeLuca GC, Palace J, MAGNIMS study group.. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2020 Apr. PMID: 32034114

  24. Tintore M, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Río J, Tur C, Comabella M, Nos C, Arévalo MJ, Anglada E, Menendez R, Midaglia L, Galán I, Vidal-Jordana A, Castilló J, Mulero P, Zabalza A, Rodríguez-Acevedo B, Rodriguez M, Espejo C, Sequeira J, Mitjana R, de Barros A, Pareto D, Auger C, Pérez-Hoyos S, Sastre-Garriga J, Rovira A, Montalban X. The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Mult Scler. 2020 Nov. PMID: 31610739

  25. Feys P, Sastre-Garriga J. Editorial. Mult Scler. 2019 Sep. PMID: 31469353

  26. Pareto D, Sastre-Garriga J, Alberich M, Auger C, Tintoré M, Montalban X, Rovira À. Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology. 2019 Jun. PMID: 30834955

  27. Zuluaga MI, Otero-Romero S, Rovira A, Perez-Hoyos S, Arrambide G, Negrotto L, Galán I, Río J, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez B, Midaglia L, Mulero P, Mitjana R, Auger C, Sastre-Garriga J, Montalban X, Tintoré M. Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology. 2019 Mar 26. PMID: 30824557

  28. Pappolla A, Midaglia L, Boix Rodríguez CP, Puig AA, Lung M, Camps IR, Castilló J, Mulero P, Vidal-Jordana A, Arrambide G, Rodriguez-Acevedo B, Sastre-Garriga J, Río J, Comabella M, Galán I, Tintoré M, Montalbán X. Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. Neurology. 2019 Feb 5. PMID: 30587519

  29. Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N, the MAGNIMS Study Group.. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. Neurology. 2019 Jan 22. PMID: 30587516

  30. Giordano A, Liethmann K, Köpke S, Poettgen J, Rahn AC, Drulovic J, Beckmann Y, Sastre-Garriga J, Galea I, Heerings M, Jongen PJ, Vettorazzi E, Solari A, Heesen C, AutoMS group.. Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey. PLoS One. 2018. PMID: 30496233

  31. Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Multiple sclerosis registries in Europe - An updated mapping survey. Mult Scler Relat Disord. 2019 Jan. PMID: 30384204

  32. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019 Jan. PMID: 30315270

  33. Rocca MA, Barkhof F, De Luca J, Frisén J, Geurts JJG, Hulst HE, Sastre-Garriga J, Filippi M, MAGNIMS Study Group.. The hippocampus in multiple sclerosis. Lancet Neurol. 2018 Oct. PMID: 30264730

  34. Midaglia L, Gratacòs M, Caronna E, Raguer N, Sastre-Garriga J, Montalban X, Tintoré M. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. Neurology. 2018 Sep 25. PMID: 30143565

  35. Köpke S, Giordano A, Veronese S, Christin Rahn A, Kleiter I, Basedow-Rajwich B, Fornari A, Battaglia MA, Drulovic J, Kooij L, Koops J, Mens J, Meza Murillo ER, Milanov I, Milo R, Patti F, Pekmezovic T, Sastre-Garriga J, Vosburgh J, Voltz R, Bay J, Oliver DJ, Solari A. Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. Eur J Neurol. 2019 Jan. PMID: 30035845

  36. . Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary. Mult Scler. 2018 Oct. PMID: 30033805

  37. Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, Geurts JJG, Rocca MA, Sastre-Garriga J, Enzinger C, de Stefano N, Filippi M, Rovira Á, Barkhof F, Vrenken H, MAGNIMS Study Group.. Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. Neuroimage Clin. 2018. PMID: 29984155

  38. Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O. Progression of regional grey matter atrophy in multiple sclerosis. Brain. 2018 Jun 1. PMID: 29741648

  39. Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M, MAGNIMS Study Group.. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging. Radiology. 2018 Aug. PMID: 29714673

  40. Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Jacqueline Palace on behalf of the MAGNIMS study group.. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018 Mar 20. PMID: 29582852

  41. Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J, MAGNIMS study group.. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018 Apr. PMID: 29521337

  42. Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T, MAGNIMS study group.. The role of the cerebellum in multiple sclerosis-150 years after Charcot. Neurosci Biobehav Rev. 2018 Jun. PMID: 29477616

  43. Camara-Lemarroy CR, Castilló J, Sastre-Garriga J, Tintore M, Montalban X. Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. Mult Scler. 2018 Sep. PMID: 29473796

  44. Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018 Apr 1. PMID: 29462277

  45. Sastre-Garriga J, Otero-Romero S. [Remodelling of the Scientific Committee and a new series of neuroepidemiology reviews]. Rev Neurol. 2018 Feb 16. PMID: 29435965

  46. Pareto D, Sastre-Garriga J, Alonso J, Galán I, Arévalo MJ, Renom M, Montalban X, Rovira À. Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. J Neuroimaging. 2018 May. PMID: 29400912

  47. Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O, MAGNIMS study group.. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. 2018 Feb. PMID: 29331092

  48. Tur C, Moccia M, Barkhof F, Chataway J, Sastre-Garriga J, Thompson AJ, Ciccarelli O. Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol. 2018 Feb. PMID: 29326424

  49. . "Brain reserve" and "cognitive reserve" should always be taken into account when studying neurodegeneration - NO. Mult Scler. 2018 Apr. PMID: 29318919

  50. Aymerich FX, Auger C, Alonso J, Alberich M, Sastre-Garriga J, Tintoré M, Montalban X, Rovira A. Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. AJNR Am J Neuroradiol. 2018 Feb. PMID: 29284602

  51. Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis]. Rev Neurol. 2018 Jan 1. PMID: 29251340

  52. Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X. Lesion topographies in multiple sclerosis diagnosis: A reappraisal. Neurology. 2017 Dec 5. PMID: 29101276

  53. Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler. 2018 Dec. PMID: 28984163

  54. de Sitter A, Steenwijk MD, Ruet A, Versteeg A, Liu Y, van Schijndel RA, Pouwels PJW, Kilsdonk ID, Cover KS, van Dijk BW, Ropele S, Rocca MA, Yiannakas M, Wattjes MP, Damangir S, Frisoni GB, Sastre-Garriga J, Rovira A, Enzinger C, Filippi M, Frederiksen J, Ciccarelli O, Kappos L, Barkhof F, Vrenken H, MAGNIMS study group and for neuGRID.. Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. Neuroimage. 2017 Dec. PMID: 28899746

  55. Preziosa P, Rocca MA, Mesaros S, Meani A, Montalban X, Drulovic J, Droby A, Zipp F, Calabrese M, Sastre-Garriga J, Dujmovic-Basuroski I, Rovira A, Filippi M. Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. J Neurol Neurosurg Psychiatry. 2018 Mar. PMID: 28724720

  56. Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X. Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. AJNR Am J Neuroradiol. 2017 Aug. PMID: 28619842

  57. Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X. Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Mult Scler. 2018 May. PMID: 28445084

  58. Sastre-Garriga J, Pareto D, Rovira À. Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects. Neuroimaging Clin N Am. 2017 May. PMID: 28391787

  59. Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M. Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Mult Scler. 2018 Mar. PMID: 28301287

  60. Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. Mult Scler. 2018 Mar. PMID: 28287331

  61. . [New areas, new challenges...] Rev Neurol. 2017 Mar 1. PMID: 28229438

  62. Vidal-Jordana A, Pareto D, Sastre-Garriga J, Auger C, Ciampi E, Montalban X, Rovira A. Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. AJNR Am J Neuroradiol. 2017 Feb. PMID: 27884876

  63. Tintore M, Otero-Romero S, Río J, Arrambide G, Pujal B, Tur C, Galán I, Comabella M, Nos C, Arévalo MJ, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Midaglia L, Mitjana R, Auger C, Sastre-Garriga J, Rovira À, Montalban X. Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology. 2016 Sep 27. PMID: 27566747

  64. Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13. PMID: 27521440

  65. Aymerich FX, Auger C, Alcaide-Leon P, Pareto D, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Montalban X, Rovira A. Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. Eur Radiol. 2017 Apr. PMID: 27456965

  66. Tintoré M, Sastre-Garriga J. Multiple sclerosis: Dimethyl fumarate is coming of age. Nat Rev Neurol. 2016 Aug. PMID: 27448183

  67. Ciampi E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, Tur C, Río J, Tintoré M, Auger C, Rovira A, Montalban X. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Mult Scler. 2017 Apr. PMID: 27354019

  68. . [A message from the new Editor of the Revista de Neurologia]. Rev Neurol. 2016 Jun 16. PMID: 27270673

  69. Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016 Oct. PMID: 27207462

  70. . Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: Time to expect the unexpected? Mult Scler. 2016 Jun. PMID: 27207451

  71. Comabella M, Sastre-Garriga J, Montalban X. Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. Curr Opin Neurol. 2016 Jun. PMID: 27075495

  72. Midaglia L, Juega Mariño JM, Sastre-Garriga J, Rovira A, Vidal-Jordana A, López-Pérez MA, Marzo-Sola ME, Librada Escribano F, Montalban X. An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. Mult Scler. 2016 May. PMID: 26993120

  73. Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Pareto D, Rio J, Auger C, Tintoré M, Rovira A, Montalban X. Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. J Neuroimaging. 2016 Sep. PMID: 26935253

  74. Pareto D, Sastre-Garriga J, Aymerich FX, Auger C, Tintoré M, Montalban X, Rovira A. Lesion filling effect in regional brain volume estimations: a study in multiple sclerosis patients with low lesion load. Neuroradiology. 2016 May. PMID: 26847633

  75. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F, MAGNIMS Study Group.. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016 Mar. PMID: 26822746

  76. Valverde S, Oliver A, Roura E, Pareto D, Vilanova JC, Ramió-Torrentà L, Sastre-Garriga J, Montalban X, Rovira À, Lladó X. Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. Neuroimage Clin. 2015. PMID: 26740917

  77. Sastre-Garriga J, Wiendl H. Highlights from the 31st ECTRIMS congress - Barcelona 2015. Mult Scler. 2016 Jan. PMID: 26684283

  78. Enzinger C, Pinter D, Rocca MA, De Luca J, Sastre-Garriga J, Audoin B, Filippi M. Longitudinal fMRI studies: Exploring brain plasticity and repair in MS. Mult Scler. 2016 Mar. PMID: 26683590

  79. Otero-Romero S, Ramió-Torrentà L, Pericot I, Carmona O, Perkal H, Saiz A, Bufill E, Robles R, Simón E, Llufriu S, Vaqué-Rafart J, Sastre-Garriga J, Montalban X. Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe. J Neurol Sci. 2015 Dec 15. PMID: 26671104

  80. Pareto D, Sastre-Garriga J, Auger C, Vives-Gilabert Y, Delgado J, Tintoré M, Montalban X, Rovira A. Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis. AJNR Am J Neuroradiol. 2015 Dec. PMID: 26450537

  81. Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X. Predictive value of early brain atrophy on response in patients treated with interferon β. Neurol Neuroimmunol Neuroinflamm. 2015 Aug. PMID: 26185778

  82. Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X. Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol. 2015 Dec. PMID: 26041617

  83. Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana A, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul. PMID: 25902415

  84. Negrotto L, Tur C, Tintoré M, Arrambide G, Sastre-Garriga J, Río J, Comabella M, Nos C, Galán I, Vidal-Jordana A, Simon E, Castilló J, Palavra F, Mitjana R, Auger C, Rovira À, Montalban X. Should we systematically test patients with clinically isolated syndrome for auto-antibodies? Mult Scler. 2015 Dec. PMID: 25778697

  85. Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis]. Rev Neurol. 2015 Feb 16. PMID: 25670046

  86. Sastre-Garriga J, Tur C, Pareto D, Vidal-Jordana A, Auger C, Río J, Huerga E, Tintoré M, Rovira A, Montalban X. Brain atrophy in natalizumab-treated patients: A 3-year follow-up. Mult Scler. 2015 May. PMID: 25392330

  87. Vidal-Jordana A, Tintoré M, Tur C, Pérez-Miralles F, Auger C, Río J, Nos C, Arrambide G, Comabella M, Galán I, Castilló J, Sastre-Garriga J, Rovira A, Montalban X. Significant clinical worsening after natalizumab withdrawal: Predictive factors. Mult Scler. 2015 May. PMID: 25392320

  88. Montalban X, Sastre-Garriga J. Diagnosis and trials of clinically isolated syndrome. Lancet Neurol. 2014 Oct. PMID: 25192850

  89. Arrambide G, Sastre-Garriga J. Predictive markers of disease evolution after a CIS in everyday practice. J Neurol Sci. 2014 Aug 15. PMID: 24881867

  90. Flachenecker P, Buckow K, Pugliatti M, Kes VB, Battaglia MA, Boyko A, Confavreux C, Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L, Kasilingam E, Koch-Henriksen N, Kuhle J, Lepore V, Middleton R, Myhr KM, Orologas A, Otero S, Pitschnau-Michel D, Rienhoff O, Sastre-Garriga J, Schyns-Liharska T, Sutovic D, Thalheim C, Trojano M, Vlasov YV, Yaldizli O, EUReMS Consortium.. Multiple sclerosis registries in Europe - results of a systematic survey. Mult Scler. 2014 Oct. PMID: 24777278

  91. Heesen C, Bruce J, Feys P, Sastre-Garriga J, Solari A, Eliasson L, Matthews V, Hausmann B, Ross AP, Asano M, Imonen-Charalambous K, Köpke S, Clyne W, Bissell P. Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report. Mult Scler. 2014 Nov. PMID: 24756569

  92. Río J, Rovira A, Tintoré M, Sastre-Garriga J, Castilló J, Auger C, Nos C, Comabella M, Tur C, Vidal Á, Montalbán X. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Mult Scler. 2014 Oct. PMID: 24622350

  93. Jarius S, Kleffner I, Dörr JM, Sastre-Garriga J, Illes Z, Eggenberger E, Chalk C, Ringelstein M, Aktas O, Montalban X, Fechner K, Stöcker W, Ringelstein EB, Paul F, Wildemann B. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation. 2014 Mar 8. PMID: 24606999

  94. Penner IK, Sastre-Garriga J. One step forward in the quest for evidence of the efficacy of cognitive rehabilitation in multiple sclerosis. Mult Scler. 2014 Jan. PMID: 24347477

  95. Tur C, Tintoré M, Vidal-Jordana Á, Bichuetti D, Nieto González P, Arévalo MJ, Arrambide G, Anglada E, Galán I, Castilló J, Nos C, Río J, Martín MI, Comabella M, Sastre-Garriga J, Montalban X. Risk acceptance in multiple sclerosis patients on natalizumab treatment. PLoS One. 2013. PMID: 24340060

  96. Lucas-Carrasco R, Sastre-Garriga J, Galán I, Den Oudsten BL, Power MJ. Preliminary validation study of the Spanish version of the satisfaction with life scale in persons with multiple sclerosis. Disabil Rehabil. 2014. PMID: 23962197

  97. Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler. 2014 Jan. PMID: 23812283

  98. Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A, Castilló J, Auger C, Huerga E, Rovira A, Montalban X. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler. 2013 Dec. PMID: 23652215

  99. Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H, MAGNIMS Study Group.. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Oct. PMID: 23524331

  100. Rovira À, Sastre-Garriga J, Auger C, Rovira A. Idiopathic inflammatory demyelinating diseases of the brainstem. Semin Ultrasound CT MR. 2013 Apr. PMID: 23522777

Publications are shown automatically from PubMed. For this reason incorrect publications may appear or we may be missing some publications.


View more...